Ipamorelin

Also known as: NNC 26-0161

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Its mechanism involves binding to GHS-R1a in the pituitary and hypothalamus, leading to a potent and dose-dependent release of growth hormone (GH) from somatotroph cells. Unlike natural ghrelin or some other GHS-R1a agonists, ipamorelin demonstrates high selectivity, resulting in minimal stimulation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, which reduces the risk of unwanted endocrine side effects. Key research findings from preclinical and clinical studies indicate that ipamorelin effectively increases GH and insulin-like growth factor 1 (IGF-1) levels in a pulsatile manner, mimicking physiological GH secretion. In clinical trials, it has shown potential for conditions such as growth hormone deficiency, frailty in elderly populations, and postoperative ileus, where it accelerates gastrointestinal motility via ghrelin receptor activation. Notably, ipamorelin has been investigated for its ability to preserve lean body mass and improve functional outcomes without significant adverse effects on glucose metabolism or adrenal function. Clinically, ipamorelin is primarily studied for its anabolic and pro-motility properties, with applications in muscle wasting disorders, recovery from surgery, and age-related sarcopenia. Its favorable safety profile—lacking the cortisol and prolactin elevations seen with other GH secretagogues—makes it a candidate for long-term use in GH-deficient states. However, it remains an investigational compound, and its use is not yet approved by major regulatory agencies for general medical practice. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides